HLS Therapeutics Inc (HLS) Stock Forecast & Price Target

Compare

44 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HLS Analyst Ratings

Moderate Buy

2 Buy

2 Hold

0 Sell

Based on 4 analysts giving stock ratings to

HLS

Therapeutics Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HLS Stock 12 Month Forecast

Average Price Target

C$7.06

▲(40.92% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for HLS Therapeutics Inc in the last 3 months. The average price target is C$7.06 with a high forecast of C$12.00 and a low forecast of C$4.00. The average price target represents a 40.92% change from the last price of C$5.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"C$2","13":"C$13","4.75":"C$4.75","7.5":"C$7.5","10.25":"C$10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$7.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.75,7.5,10.25,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Jan<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.58,6.073846153846154,6.567692307692308,7.061538461538461,7.555384615384615,8.04923076923077,8.543076923076923,9.036923076923078,9.53076923076923,10.024615384615384,10.518461538461539,11.012307692307692,11.506153846153847,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.58,5.693846153846154,5.8076923076923075,5.921538461538462,6.035384615384615,6.149230769230769,6.263076923076923,6.3769230769230765,6.490769230769231,6.604615384615384,6.718461538461538,6.832307692307692,6.9461538461538455,{"y":7.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.58,5.458461538461538,5.336923076923077,5.2153846153846155,5.093846153846154,4.972307692307693,4.850769230769231,4.729230769230769,4.607692307692307,4.486153846153846,4.364615384615385,4.243076923076924,4.121538461538462,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.47,"date":1706745600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetC$12.00

Average Price TargetC$7.06

Lowest Price TargetC$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Martin PhD

Bloom Burton

C$9.5→C$12

Buy

139.52%

Upside

Reiterated

11/19/25

Positive Outlook for HLS Therapeutics Inc. Amid Regulatory Developments and Product Approvals

Michael W. Freeman

Raymond James

C$6→C$7

Buy

39.72%

Upside

Reiterated

11/18/25

Raymond James Sticks to Its Buy Rating for HLS Therapeutics Inc (HLS)We maintain our Outperform rating and increase our PT to $7.00.

Justin Keywood

Stifel Nicolaus

C$4

Hold

-20.16%

Downside

Reiterated

11/17/25

Stifel Nicolaus Sticks to Its Hold Rating for HLS Therapeutics Inc (HLS)

Bryce Generon

TR | OpenAI - 4o

C$5→C$4.5

Hold

-10.18%

Downside

Reiterated

11/14/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$5→C$5.25

Hold

4.79%

Upside

Reiterated

11/14/25

Canaccord Genuity Remains a Hold on HLS Therapeutics Inc (HLS)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$4.5→C$5

Hold

-0.20%

Downside

Reiterated

08/15/25

Canaccord Genuity Sticks to Its Hold Rating for HLS Therapeutics Inc (HLS)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$4.25

Hold

-15.17%

Downside

Reiterated

03/13/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Martin PhD

Bloom Burton

C$9.5→C$12

Buy

139.52%

Upside

Reiterated

11/19/25

Positive Outlook for HLS Therapeutics Inc. Amid Regulatory Developments and Product Approvals

Michael W. Freeman

Raymond James

C$6→C$7

Buy

39.72%

Upside

Reiterated

11/18/25

Raymond James Sticks to Its Buy Rating for HLS Therapeutics Inc (HLS)We maintain our Outperform rating and increase our PT to $7.00.

Justin Keywood

Stifel Nicolaus

C$4

Hold

-20.16%

Downside

Reiterated

11/17/25

Stifel Nicolaus Sticks to Its Hold Rating for HLS Therapeutics Inc (HLS)

Bryce Generon

TR | OpenAI - 4o

C$5→C$4.5

Hold

-10.18%

Downside

Reiterated

11/14/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$5→C$5.25

Hold

4.79%

Upside

Reiterated

11/14/25

Canaccord Genuity Remains a Hold on HLS Therapeutics Inc (HLS)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$4.5→C$5

Hold

-0.20%

Downside

Reiterated

08/15/25

Canaccord Genuity Sticks to Its Hold Rating for HLS Therapeutics Inc (HLS)

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

C$4.25

Hold

-15.17%

Downside

Reiterated

03/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering HLS Therapeutics Inc

1 Month

xxx

Success Rate

16/36 ratings generated profit

Average Return

+10.24%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of +10.24% per trade.

3 Months

xxx

Success Rate

17/36 ratings generated profit

Average Return

+8.99%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.22% of your transactions generating a profit, with an average return of +8.99% per trade.

1 Year

David Martin PhDBloom Burton

Success Rate

15/36 ratings generated profit

Average Return

+10.79%

reiterated a buy rating 9 days ago

Copying David Martin PhD's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +10.79% per trade.

2 Years

xxx

Success Rate

14/36 ratings generated profit

Average Return

+4.96%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 38.89% of your transactions generating a profit, with an average return of +4.96% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HLS Analyst Recommendation Trends

Rating

May 25

Jul 25

Aug 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HLS has received 5 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. HLS average Analyst price target in the past 3 months is 7.06.

Each month's total comprises the sum of three months' worth of ratings.

HLS Financial Forecast

HLS Earnings Forecast

Next quarter’s earnings estimate for HLS is -C$0.04 with a range of -C$0.10 to C$0.01. The previous quarter’s EPS was -C$0.17. HLS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year HLS has Performed in-line its overall industry.

HLS Sales Forecast

Next quarter’s sales forecast for HLS is C$21.16M with a range of C$20.58M to C$21.42M. The previous quarter’s sales results were C$18.61M. HLS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year HLS has Performed in-line its overall industry.

HLS Stock Forecast FAQ

What is TSE:HLS’s average 12-month price target, according to analysts?

Based on analyst ratings, HLS Therapeutics Inc’s 12-month average price target is 7.06.

What is TSE:HLS’s upside potential, based on the analysts’ average price target?

HLS Therapeutics Inc has 40.92% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TSE:HLS a Buy, Sell or Hold?

HLS Therapeutics Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.

What is HLS Therapeutics Inc’s price target?

The average price target for HLS Therapeutics Inc is 7.06. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is C$12.00 ,the lowest forecast is C$4.00. The average price target represents 40.92% Increase from the current price of C$5.01.

What do analysts say about HLS Therapeutics Inc?

HLS Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of TSE:HLS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

HLS Therapeutics Inc (HLS) Stock Forecast & Price Target

HLS Analyst Ratings

HLS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering HLS Therapeutics Inc

HLS Analyst Recommendation Trends

HLS Financial Forecast

HLS Earnings Forecast

HLS Sales Forecast

HLS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts